

**IACH 2020 WORKING Program**  
**Meeting co-chairs:** Mohamad Mohty, Arnon Nagler, Jordi Sierra  
**Local co-chairs:** Didier Blaise, Thomas Cluzeau

<b>Thursday, October 1, 2020</b>	
	<b>Hall A</b>
<b>14:30-15:40</b>	<b>Session 1: The 2020 highlights in ...</b>
14:30-14:50	... high-risk AML: <b>Arnon Nagler</b> , Israel
14:50-15:10	... CML: <b>François Guilhot</b> , France
15:10-15:30	... MDS: <b>Thomas Cluzeau</b> , France
15:30-15:40	Discussion
<b>15:40-16:30</b>	<b>Session 2: Advances in AML biology</b>
15:40-16:00	Role of NPM1 mutation: <b>Brunangelo Falini</b> , Italy
16:00-16:20	Impact of microbiota modulation: <b>Florent Malard</b> , France
16:20-16:30	Discussion
<b>16:30-16:40</b>	<b>Technical Break</b>
<b>16:40-18:00</b>	<b>Session 3: The hard to treat patients</b>
16:40-17:00	Relapsed/refractory B-ALL: <b>Dieter Hoelzer</b> , Germany
17:00-17:20	Relapsed/refractory T-ALL: <b>Eolia Brissot</b> , France
17:20-17:40	Transplant for refractory AML: <b>Mohamad Mohty</b> , France
17:40-18:00	Discussion
<b>18:00-19:00</b>	<b>Session 4: Opening lectures and H.J. Khoury award</b>
18:00-18:30	Award presentation officiated by: <b>Mohamad Mohty</b> , France and <b>Arnon Nagler</b> , Israel
18:30-19:00	<i>Keynote award lecture - TBA</i>

<b>Friday, October 2, 2020</b>	
	<b>Hall A</b>
<b>08:30-10:00</b>	<b>Session 5: Remission and post-remission therapy in high-risk acute leukemia</b>
08:30-08:50	Induction therapy in AML: <b>Michael Loschi</b> , France
08:50-09:10	Allo-transplant in AML: <b>Jordi Sierra</b> , Spain
09:10-09:30	Autologous transplantation in AML: <b>Norbert-Claude Gorin</b> , France
09:30-09:50	Allo-transplant in ALL: <b>Sebastian Giebel</b> , Poland
09:50-10:00	Discussion
<b>10:00-10:10</b>	<b>Technical Break</b>
<b>10:10-11:40</b>	<b>Industry Sponsored Symposium on VOD</b>
<b>11:40-11:50</b>	<b>Technical Break</b>
<b>11:50-13:20</b>	<b>Session 6: CAR-T cells in ALL</b>
11:50-12:10	Recent results in children: <b>André Baruchel</b> , France
12:10-12:30	Recent results in adults: <b>Christian Chabannon</b> , France
12:30-12:50	Experience from China: <b>He Huang</b> , China
12:50-13:10	Management of toxicities: <b>Jordan Gauthier</b> , USA
13:10-13:20	Discussion
<b>13:20-13:50</b>	<b>Lunch Break</b>
<b>13:50-15:40</b>	<b>Session 7: Management of elderly leukemia</b>
13:50-14:10	ALL in older and medically infirm patients: choice of therapies: <b>Mohamed Sorrow</b> , USA
14:10-14:30	AML: <b>Farhad Ravandi</b> , USA
14:30-14:50	Transplant for elderly leukemia: <b>Didier Blaise</b> , France
14:50-15:10	Supportive care: <b>Bipin Savani</b> , USA
15:10-15:30	Transplant for MDS: <b>Ibrahim Yakoub-Agha</b> , France
15:30-15:40	Discussion
<b>15:40-15:50</b>	<b>Technical Break</b>
<b>15:50-16:30</b>	<b>Industry Sponsored Symposium on AML</b>

<b>Saturday, October 3, 2020</b>	
	<b>Hall A</b>
<b>08:30-10:00</b>	<b>Session 9: Management of rare leukemias</b>
08:30-08:50	Plasmacytoid dendritic cell leukemia: <b>Naveen Pemmaraju</b> , USA
08:50-09:10	Mastocytosis: <b>Olivier Hermine</b> , France
09:10-09:30	ATL and HTLV-related disorders: <b>Ali Bazarbachi</b> , Lebanon
09:30-09:50	Acute promyelocytic leukemia: <b>Miguel Sanz</b> , Spain
09:50-10:00	Discussion
<b>10:00-10:10</b>	<b>Technical Break</b>
<b>10:10-11:20</b>	<b>Session 10: Novel drugs in leukemia</b>
10:10-10:30	BTK inhibitors: <b>Gianluca Gaidano</b> , Italy
10:30-10:50	Antibody-drug conjugates: <b>Norbert Vey</b> , France
10:50-11:10	BCL-2 inhibitors: <b>Thomas Prebet</b> , USA
11:10-11:20	Discussion
<b>11:20-11:50</b>	<b>Lunch Break</b>
<b>11:50-13:00</b>	<b>Closing lectures</b>
11:50-12:10	Advances in ALL therapy: <b>Hagop Kantarjian</b> , USA
12:10-12:30	Flt3 inhibitors in AML: <b>Richard Stone</b> , USA
12:30-12:50	Novel drugs development, evaluation and access: <b>Jean-Luc Harousseau</b> , France
12:50-13:00	Final discussion and closing remarks: <b>Mohamad Mohty</b> , France; <b>Arnon Nagler</b> , Israel